Sponsored by
Education only. Not investment or medical advice.
Welcome Back, Longevity Investors.
Today, three longevity biotechs scored on both returns: the healthy years they could add and the business behind them. Let's dive in!
In today's issue:
This AI Drug Turned Aging Clocks Back 3 To 4 Years. Its Maker Just Turned A Profit.
Longeveron Has Frailty Data, But Cash Only Lasts Into Q4
A $1.8B Startup Is Testing A Pill To Restart Cell Cleanup In People
Plus: an investor tip, quick hits, dated milestones and money moves
Read time: 5 minutes
Longevity Biotechs On The Move
🤖 AI DRUG
This AI Drug Turned Aging Clocks Back 3 To 4 Years. Its Maker Just Turned A Profit.
Source: Insilico Medicine, Aug 26, Sept 10 and Sept 14, 2026; GEN
EverLife: Could it add healthy years? Insilico Medicine's rentosertib, an AI-designed drug for lung scarring (IPF), made six blood-protein aging clocks trend younger than placebo. Is the business strong? Insilico reported its first profit: $35.5M on $106.3M of revenue in the first half of 2026, which is rare for a biotech.
Key Points:
42 patients: about 3 to 4 years younger on several clocks, up to 6 on one
Phase 3 underway: 320 patients at 47 centers in China
Cash: $393M at the end of 2025
Partner deals with Eli Lilly (up to $2.75B) and Sanofi (up to $1.2B)
Details: The aging result is exploratory, with no significance tests reported, and the best lung dose wasn't the dose with the strongest clock signal. Deal values are mostly milestones that may never be paid.
🌍 Where it trades: Hong Kong (HKEX: 3696). Many US and Canadian brokers don't offer Hong Kong shares, so readers usually need a broker with international market access.
Dual ROI
🩺 Health: It's a lung-disease drug first, and any anti-aging use would need its own trials. A trial investigator estimates 3 to 4 years from Phase 3 start to approval, under favorable conditions.
📈 Investors: It earns from drug-discovery deals as well as its own pipeline, which spreads risk across many programs instead of riding on one.
Bad news is good business. We never bought in.
Every morning, financial news follows the same script. Headlines panic, coverage catastrophises, and somewhere inside the noise is the story that actually matters — the one that tells you where the opportunity sits, not just where the fear is pointing.
Most sources have stopped looking. The alarm is easier to sell.
The Daily Upside was created by Wall Street insiders for readers who crave real insight over recycled anxiety. Five minutes of global business and finance, before the noise sets the agenda — just the facts, context, and analysis your decisions need.
Join 1M readers — including managing directors and principals at some of Wall Street’s largest institutions — who trust The Daily Upside to filter through the chaos.
The upsides are always there. We’ll find them before breakfast.
🫀 FRAILTY
Longeveron Has Frailty Data, But Cash Only Lasts Into Q4
Source: Longeveron releases, Aug and Sept 16, 2026
EverLife: Could it add healthy years? Longeveron's laromestrocel, made from donor stem cells, improved physical condition at 9 months vs placebo in older adults with frailty (Phase 2b, published in Cell Stem Cell in February). Is the business strong? Not right now: a September trial miss in infants with a heart defect sent the stock down about 59%.
Key Points:
$1M XPRIZE Healthspan finalist award for its frailty program
Alzheimer's: FDA Fast Track and RMAT designations; seeking a partner
Cash: $10.1M on June 30, enough into Q4 2026 (now), per the company, with no new funding announced as of Oct 19
Details: That heart trial had 40 patients (p=0.83) and clean safety. The company is reviewing strategic options with an investment bank adviser and conserving cash.
🌍 Where it trades: US (NASDAQ: LGVN), available at most US and Canadian brokers.
Dual ROI
🩺 Health: Frailty is a leading reason older adults lose independence. A therapy that reverses it would matter, but it needs larger trials first.
📈 Investors: New money would likely dilute current shareholders, and a strategic review can end in a sale, a merger or a financing.
🧠 BRAIN AGING
A $1.8B Startup Is Testing A Pill To Restart Cell Cleanup In People
Source: Retro Biosciences, May 22, 2026; Longevity.Technology
EverLife: Could it add healthy years? Retro Biosciences' RTR242 is a pill designed to restart autophagy, the cleanup system that clears damaged proteins and slows with age. The first target is Alzheimer's. Is the business strong? It is well funded, with Sam Altman as its biggest early backer.
Key Points:
First human trial (Phase 1) underway in Australia, testing safety
Target choice to first human dose in 15 months, per the company
Other programs: blood stem-cell therapy, tissue reprogramming and AI protein design
Details: Altman put about $180M into Retro in 2023. A May round led by 4P Capital valued it at $1.8B before the new money.
🌍 Where it trades: Private, so most readers can't invest yet.
Dual ROI
🩺 Health: Failing cellular cleanup is linked to Alzheimer's, Parkinson's and other diseases of aging. A pill that safely restores it could matter for several of these diseases at once.
📈 Investors: That price, set before any efficacy data, means a lot has to go right.
Investor Tip
Score the science and the balance sheet separately.
For each company, ask two questions: what is the best human evidence so far, and how many months of cash does it have before its next big result? A strong drug and a strong company are not the same thing.
Quick Hits
💊 Eli Lilly (NYSE: LLY): said tirzepatide (Zepbound) slowed epigenetic aging clocks in a trial analysis presented at ARDD in Boston. Like Novo's result in Monday's issue, it comes from company scientists, with no detailed numbers or peer review yet.
Enlivex (NASDAQ: ENLV): cut about 60% of its staff on Oct 19 to fund a Phase 2b trial of Allocetra, a knee injection for age-related osteoarthritis that the FDA gave a fast-track RMAT designation in July for patients 64 and older.
On The Calendar
Mid-2027: Enlivex expects 6-month Phase 2b results for Allocetra in knee osteoarthritis
Sept 2027: first patients in Insilico's rentosertib Phase 3 (started Sept 10, 2026) finish 52 weeks of dosing
Money Moves
🤖 Gero (private): $17M for AI-driven aging drug discovery, bringing total funding to $34M. Its Chugai deal carries up to $250M in milestones. (MobiHealthNews, June 19)
🧴 Rapalogix Health (private): $20M Series A co-led by Woodline Partners and GordonMD for TORC1-targeting skin longevity products and its prescription candidate RLX-202. (Startup Researcher, June 23)
You Pick The Next Story
What do you want me to dig into next?
- Heart aging: the companies trying to clear plaque from old arteries, and which are public
- Billionaire-backed longevity startups: which ones regular investors can actually buy
- Longevity drugs you might be able to get within 5 years, and who makes them
- Outside the US: the most promising longevity biotechs in Japan, the UK and Europe
- Something else: tell me what on the next page
For Members
Members get my 25-gate Dual ROI scores on longevity companies and see which ones I'm watching most closely.
How was today's issue?
Know someone who wants more healthy years? Forward this. Got this from a friend? Join free here.
Eric
This newsletter is general and impersonal. Nothing in it is a recommendation to buy, sell or hold any security, and it doesn't consider your circumstances. Nothing here is an offer to sell or a solicitation of an offer to buy any security. Company plans and dates are the companies' own statements, not my forecasts.
I hold no position in, and receive no pay from, any company named here. I hold personal equity in Repair Biotechnologies and Yuva Biosciences, neither discussed here. Treatments mentioned are experimental unless noted as approved. Full disclosure and terms.